GOOSMs / GenOdyssee - LARVOL DELTA

Exercise-Induced Changes in Serum Oncostatin M Levels in Recreationally Active Males (clinicaltrials.gov) - P=N/A | N=15 | Completed | Sponsor: Hacettepe University

New trial

The Diagnostic Value of Serum Oncostatin M and Galactin 3 as Biomarkers in Diagnosis of Ulcerative Colitis Disease (clinicaltrials.gov) - P=N/A | N=90 | Not yet recruiting | Sponsor: Sohag University

Biomarker • New trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Study of the Role of Oncostatin M in Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P=N/A | N=119 | Not yet recruiting | Sponsor: Poitiers University Hospital

New trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • IL10 • IL17A • IL1B • IL34 • IL6 • TNFA

Oncostatin M in Ulcerative Colitis Patients (clinicaltrials.gov) - P=N/A | N=99 | Not yet recruiting | Sponsor: Beni-Suef University

New trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

COSMIS: Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease (clinicaltrials.gov) - P2a/2b; N=0; Withdrawn; Sponsor: GlaxoSmithKline; N=280 ➔ 0; Trial completion date: Dec 2024 ➔ May 2025; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Nov 2023 ➔ Apr 2024

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

Measurement of Oncostatin M, Leukemia Inhibitory Factor and Interleukin-11 Levels of Patients With Periodontal Disease (clinicaltrials.gov) - P=N/A; N=72; Completed; Sponsor: Ataturk University

Clinical • New trial • Dental Disorders • Hematological Malignancies • Leukemia • Oncology • Periodontitis

COSMIS: Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease (clinicaltrials.gov) - P2a/2b; N=280; Not yet recruiting; Sponsor: GlaxoSmithKline; Trial completion date: May 2024 ➔ Dec 2024; Initiation date: Jun 2020 ➔ Jan 2021; Trial primary completion date: Apr 2023 ➔ Nov 2023

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • CRP

COSMIS: Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease (clinicaltrials.gov) - P2a/2b; N=280; Not yet recruiting; Sponsor: GlaxoSmithKline; Trial completion date: Feb 2024 ➔ May 2024; Initiation date: Mar 2020 ➔ Jun 2020; Trial primary completion date: Jan 2023 ➔ Apr 2023

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • CRP